THE ARISING · DAILY EDITION
The Arising — October 13, 2026
Download the PDF ↓Longevity & Healthspan
Keto Diet Raised Small Intestine Tumors in Cancer-Prone Mice, MIT Finds
A ketogenic diet sped up tumor growth and shortened survival in mice bred to develop intestinal cancer, according to a new study in Nature, and the cause was not the ketones that the diet is named for.
Longevity in daily life →Study Projects 24.7 Million New Dementia Cases in 2050 if Rates Hold
About 24.7 million people worldwide could develop dementia in 2050, according to a new analysis in JAMA Neurology, if today's rates hold.
Brain health →Study of 300 Million Lab Tests Finds Abrupt Body Changes at Menopause
Menopause may change the body more suddenly than doctors have long thought. A new analysis of routine blood tests reports a sharp, step-like shift in several body systems at a woman's final menstrual period, and that finding is already being challenged.
Reading medical evidence →Gut Bacteria Fatty Acid C15:0 Halved Artery Plaque in Mice
A fatty acid made by a common gut bacterium cut artery plaque by around 50% in mice, according to a study in Nature.
Reading medical evidence →AI Reading Heart Signals During Sleep Studies Predicts 10-Year Cardiovascular Risk
A night in a sleep lab already records the heart. Researchers now report that a computer model reading those rarely examined heart traces can help estimate a person's risk of atrial fibrillation, heart failure and early death over the next 10 years.
Sleep →
Markets & Strategy
England and Wales Mortality Hits Record Nine-Month Low, Pressuring Annuity Pricing
People in England and Wales are dying at the lowest rate on record for the first three quarters of a year, and that is bad news for the firms that have promised to pay them pensions for life.
Reading medical evidence →Parkinson's Stem Cell Developer Aspen Neuroscience Files for Nasdaq IPO
Aspen Neuroscience, a San Diego company that makes a Parkinson's cell therapy from a patient's own skin cells, has filed publicly for a Nasdaq IPO, according to Renaissance Capital. The therapy, sasineprocel, is investigational and not approved or available outside clinical trials.
Brain health →IMF Says AI Productivity Gains Could Outweigh Asia's Aging-Driven Workforce Decline
Asia's aging populations may not drag down its growth if artificial intelligence delivers, according to the International Monetary Fund. This account rests on a secondhand summary of Investing.com's report, because the underlying page could not be fetched.
Reading medical evidence →UCSF Details How FDA's Bone Density Endpoint Will Shrink Osteoporosis Trials
A late-stage osteoporosis trial that once needed up to 15,000 patients may now need about 750. According to UCSF News, that is the effect of an FDA decision that lets drug developers use changes in hip bone density, rather than fractures, as the main measure of success.
Reading medical evidence →Tiny Health Raises $33 Million Series B as Adult Microbiome Testing Overtakes Pediatric
A company that began by testing babies' guts now sells more tests to adults. Tiny Health, based in Austin, has raised a $33 million Series B, according to Longevity.Technology.
Longevity in daily life →